Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.
Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long-acting octreotide.
Healy
M L
ML
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Dawson
S J
SJ
Murray
R M L
RM
Zalcberg
J
J
Jefford
M
M
D000328:Adult; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000175:diagnosis; D007340:Insulinoma / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D015282:Octreotide